{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:43:05Z","timestamp":1774536185335,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":244,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dupilumab-associated ocular surface disease is a common clinical sign appearing in patients with atopic dermatitis (AD) just few months after dupilumab treatment start, developing in about 25% of patients. Atopic keratoconjunctivitis (AKC) is a well-identified clinical entity, defined as a chronic inflammatory disease of eye that affects 25%\u201340% of patients with AD. Most clinical signs of ocular involvement in AD patients treated with dupilumab overlaps the AKC symptoms and signs. We supposed that Dupilumab-associated ocular surface disease and AKC represent the same disease but differently called by dermatologists and ophthalmologists. AKC-like disease may develop during dupilumab therapy as a consequence of alternative cytokines pathway activation (e.g. IL33) secondary to IL-4\/13 pathway block. The novel upadacitinib drug may bypass ILs pathway through Janus Kinases selective inhibition, avoiding positive or negative ILs feedback at the ocular surface level. In this case report, molecular analysis on conjunctival samples showed a lower ocular surface inflammation (lower expression of HLADR) although higher levels of IL4 and IL13 in a patient with AD and AKC during upadacitinib therapy, compared to prior dupilumab treatment. Target therapies in patients suffering from AD may prevent ocular and dermatological comorbidities improving quality of life before quality of skin and vision.<\/jats:p>","DOI":"10.1002\/ski2.354","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T05:36:15Z","timestamp":1710480975000},"source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab-Associated Ocular Surface Disease or Atopic Keratoconjunctivitis Not Improved by Dupilumab? Upadacitinib May Clarify the Dilemma: A Case Report"],"prefix":"10.1093","volume":"4","author":[{"given":"Marco","family":"Galluzzo","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Tofani","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Spelta","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Micera","sequence":"additional","affiliation":[{"name":"Research and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Science, IRCCS - Fondazione Bietti , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Coassin","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Bonini","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Zazzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"1","key":"2025112605221404900_ski2354-bib-0001","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2025112605221404900_ski2354-bib-0002","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2025112605221404900_ski2354-bib-0003","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/ico.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical Characteristics, treatment, and Follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"issue":"6","key":"2025112605221404900_ski2354-bib-0004","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2025112605221404900_ski2354-bib-0005","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting","volume":"82","author":"Uchida","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2025112605221404900_ski2354-bib-0006","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"2025112605221404900_ski2354-bib-0007","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2021.09.029","article-title":"Dupilumab-induced ocular surface disease: a systematic review","volume":"86","author":"Fachler","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2025112605221404900_ski2354-bib-0008","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2025112605221404900_ski2354-bib-0009","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15575","article-title":"Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis","volume":"35","author":"Hayama","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"2025112605221404900_ski2354-bib-0010","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/derm.2022.0063","article-title":"Ocular adverse events in patients with atopic dermatitis treated with upadacitinib: a real-life experience","volume":"34","author":"Gelato","year":"2023","journal-title":"Dermat Contact Atopic Occup Drug"},{"issue":"9","key":"2025112605221404900_ski2354-bib-0011","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/exd.14859","article-title":"Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis","volume":"32","author":"Chiricozzi","year":"2023","journal-title":"Exp Dermatol"},{"issue":"1","key":"2025112605221404900_ski2354-bib-0012","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2020.09.046","article-title":"Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis","volume":"85","author":"Cheng","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2025112605221404900_ski2354-bib-0013","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1111\/jdv.17210","article-title":"Dupilumab and conjunctivitis: a case series of twenty patients","volume":"35","author":"Calabrese","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2025112605221404900_ski2354-bib-0014","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/jdv.18922","article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations","volume":"37","author":"Adam","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/3\/ski2.354\/60660580\/skinhd_4_3_e354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/3\/ski2.354\/60660580\/skinhd_4_3_e354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:22:18Z","timestamp":1764152538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.354\/7896825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.354","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,3,15]]},"article-number":"ski2.354"}}